Skip to main content

Table 1 Baseline patient characteristics

From: Higher reticulocyte counts are associated with higher mortality rates in hemodialysis patients: a retrospective single-center cohort study

Characteristics   Reticulocyte count p
All Patients Q1 Q2 Q3 Q4 ANOVA or χ 2
No. of patients 358 89 90 89 90  
Range of reticulocyte count (103/μL) 9.3 to 147.9 ≤30.1 30.2 to 39.4 39.6 to 53.6 ≤53.7  
Demographics
 Age (year) 60.2 (12.6) 60.4 (13.8) 60.4 (12.7) 61.0 (12.6) 59.1 (11.4) 0.78
 Male gender (%) 67.3 78.7 70.0 64.0 56.7 0.01
 Duration of dialysis (year) 8.5 (7.0) 7.9 (6.2) 8.8 (6.6) 8.8 (7.6) 8.7 (7.4) 0.80
Cause of renal failure
 Diabetes mellitus (%) 29.9 23.6 27.8 33.7 34.4 0.34
BMI 20.6 (3.0) 20.0 (2.4) 20.6 (3.0) 20.6 (2.8) 21.1 (3.5) 0.09
Dry weight (kg) 53.1 (10.3) 53.0 (9.0) 53.3 (12.1) 52.2 (9.1) 53.7 (10.7) 0.80
Interdialysis weight gain (%) 5.6 (1.9) 5.1 (1.9) 5.6 (1.9) 5.4 (2.0) 6.0 (1.7) 0.02
Smoking history (%) 44.9 48.8 42.9 45.3 42.5 0.84
Vascular disease history (%) 47.8 41.6 42.2 53.9 53.3 0.18
Medication
 ACE or ARB (%) 30.7 40.4 38.1 25.6 18.9 <0.01
 Injection of Fe (%) 25.1 22.5 30.0 25.8 22.2 0.60
 1w rHuEPO/week (IU/w) 3694 (3077) 3396 (2874) 4321 (2949) 3584 (3281) 3508 (3154) 0.19
 2w rHuEPO/week (IU/w) 3727 (3079) 3459 (2906) 4415 (2971) 3576 (3255) 3496 (3079) 0.13
 4w rHuEPO/week (IU/w) 3752 (3063) 3550 (2912) 4339 (2900) 3628 (3259) 3521 (3142) 0.25
Systolic blood pressure (mmHg) 151.9 (23.6) 154.8 (20.9) 155.5 (22.4) 146.8 (25.6) 150.33 (24.5) 0.05
Diastolic blood pressure (mmHg) 78.4 (11.6) 79.4 (12.1) 80.4 (11.1) 76.8 (10.0) 76.9 (13.0) 0.11
Laboratory parameters
 Reticulocyte count (103/μL) 43.4 (19.4) 22.5 (5.1) 35.1 (2.7) 45.8 (4.0) 69.6 (16.1) <0.001
 Hemoglobin (g/dL) 9.9 (1.1) 9.8 (1.2) 9.9 (1.0) 9.8 (1.0) 10.1 (1.2) 0.20
 Mean corpuscular volume (fL) 97.8 (6.8) 97.2 (6.3) 98.9 (6.2) 97.9 (7.0) 97.0 (7.7) 0.22
 White cell count (103/μL) 6.1 (2.1) 5.4 (1.5) 6.0 (1.8) 6.2 (2.2) 6.9 (2.5) <0.001
 Platelet count (103/μL) 185 (67) 172 (53) 182 (58) 187 (65) 199 (87) 0.06
 Iron (μg/dL) 57.2 (23.3) 58.9 (25.9) 60.3 (25.0) 57.2 (20.0) 52.6 (21.4) 0.13
 TSAT (%) 21.9 (10.1) 24.1 (11.8) 23.0 (10.1) 21.8 (9.1) 18.9 (8.5) <0.01
 Ferritin (ng/mL) 101 (135) 116 (167) 94 (107) 108 (160) 85 (92) 0.43
 AST (U/L) 15.9 (8.8) 15.5 (6.4) 14.8 (6.0) 17.2 (12.6) 16.1 (8.5) 0.32
 ALT (U/L) 14.2 (10.3) 13.6 (7.3) 13.7 (8.0) 15.4 (15.9) 14.0 (7.7) 0.62
 Alkaline phosphatase (U/L) 251 (101) 253 (115) 249 (78) 246 (96) 255 (114) 0.94
 Total bilirubin (mg/dL) 0.20 (0.09) 0.21 (0.10) 0.19 (0.06) 0.20 (0.10) 0.20 (0.09) 0.60
 Lactate dehydrogenase (U/L) 335 (81) 323 (70) 322 (66) 342 (83) 353 (98) 0.03
 Blood urea nitrogen (mg/dL) 77.4 (17.4) 70.1 (14.5) 80.3 (18.1) 79.1 (18.2) 80.1 (16.7) <0.001
 Creatinine (mg/dL) 11.7 (2.8) 11.5 (3.1) 12.0 (2.6) 11.5 (2.7) 11.8 (2.7) 0.63
 Corrected calcium (mg/dL) 9.30 (0.88) 9.25 (0.84) 9.19 (0.92) 9.28 (0.88) 9.48 (0.87) 0.14
 Phosphorus inorganic (mg/dL) 5.95 (1.50) 5.49 (1.42) 5.90 (1.33) 5.91 (1.56) 6.43 (1.53) <0.001
 Parathyroid hormone intact (pg/mL) 212 (191) 212 (206) 229 (172) 198 (292) 210 (184) 0.75
 Albumin (g/dL) 3.72 (0.36) 3.71 (0.35) 3.80 (0.36) 3.68 (0.76) 3.68 (0.35) 0.07
 Total protein (g/dL) 6.46 (0.51) 6.43 (0.49) 6.49 (0.50) 6.43 (0.58) 6.49 (0.50) 0.71
 Glucose (mg/dL) 135 (62) 122 (40) 128 (47) 141 (72) 149 (78) 0.01
 Total cholesterol (mg/dL) 157 (34) 147 (31) 154 (33) 162 (31) 165 (36) <0.01
 High-density lipoprotein (mg/dL) 45 (14) 43 (12) 46 (14) 46 (15) 45 (15) 0.43
 Triglyceride (mg/dL) 117 (68) 97 (48) 107 (62) 120 (62) 143 (87) <0.001
 Non-HDL (mg/dL) 112.1 (32.3) 104.2 (29.8) 108.1 (31.1) 116.4 (31.3) 119.9 (34.9) <0.01
 C-reactive protein (mg/dL) 0.57 (1.33) 0.41 (0.76) 0.45 (1.16) 0.56 (1.23) 0.86 (1.88) 0.11
 Serum erythropoietin (U/L) 16.2 (22.8) 11.0 (9.0) 12.0 (8.0) 14.7 (12.0) 26.6 (40.4) <0.001
 Kt/V 1.23 (0.25) 1.19 (0.24) 1.26 (0.27) 1.24 (0.23) 1.23 (0.24) 0.41
 Hb trend 0.5 mo (g/dL/week) n = 353 −0.02 (0.39) 0.01 (0.06) 0.08 (0.37) −0.03 (0.31) −0.12 (0.44) 0.01
 Hb trend 6 mo (g/dL/week) n = 338 0.01 (0.07) 0.03 (0.06) 0.01 (0.06) 0.00 (0.05) −0.01 (0.09) <0.01
  1. Results are displayed as mean (standard deviation). Patients were quartiled according to reticulocyte count. Q1, ≤30.1 × 103 cells/μL; Q2, 30.2 to 39.4 × 103 cells/μL; Q3, 39.6 to 53.6 × 103 cells/μL; and Q4, ≥53.7 × 103 cells/μL
  2. Note: BMI body mass index, ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, rHuEPO recombinant human erythropoietin, 1w rHuEPO/week the dose of rHuEPO per week for 1 week prior to enrollment, 2w rHuEPO/week the average dose of rHuEPO per week for 2 weeks prior to enrollment, 4w rHuEPO/week the average dose of rHuEPO per week for 4 weeks prior to enrollment, TSAT transferrin saturation, AST aspartate aminotransferase, ALT alanine aminotransferase, non-HDL non-high-density lipoprotein, Hb trend 0.5 mo hemoglobin trend untill 0.5 month, Hb tred 6 mo hemoglobin trend untill 6 months
Back to article page

Renal Replacement Therapy

ISSN: 2059-1381

Contact us